Table 1.

The clinical characteristics of the AA patients possessing HLA-A allele–lacking leukocytes

Cases						PB count				% of GPI-AP− granulocytes
Case no.	Age/sex	Original diagnosis	Disease duration, y	Treatment	Response to treatment	Leukocyte/ANC, ×109/L	Hemoglobin, g/dL	Platelet, ×109/L	Reticulocyte, ×106/L	At diagnosis	At sampling
1	84/F	SAA	8	ATG + CsA	CR	4.03/2.22	11.1	16.8	60	0.050	NE
2	79/F	NSAA	12	CsA	CR	3.62/2.36	12.3	133	63	0.022	0.001
3	38/F	NSAA	14	CsA	CR	5.47/4.44	11.9	136	75	1.050	0.001
4	92/F	SAA	17	CsA	CR	3.43/1.67	11.8	98	38	0.005	NE
5	44/M	SAA	11	AS	CR	3.92/2.88	13.7	182	37	0	NE
6	66/F	SAA	16	ATG + CsA	CR	5.78/3.29	10.9	196	49	0.367	NE
7	39/F	VSAA	15	ATG + CsA	CR	4.57/2.58	14.3	173	68	0	NE
8	74/F	NSAA	25	CsA	CR	4.21/2.31	13.9	167	NE	0	NE
9	27/M	NSAA	14	ATG + CsA	CR	2.44/1.30	14.8	132	68	1.140	0.052
10	42/M	SAA	10	CsA	CR	3.00/1.74	14.3	159	63	0.180	NE
11	54/M	NSAA	2	CsA + AS	CR	3.21/1.54	12.3	109	75	3.500	NE
12	53/F	VSAA	3	Romiplostim	CR	6.30/3.81	14.2	147	47	0	NE
13	50/M	NSAA	30	CsA + AS	CR	4.32/2.57	14.4	78	35	0	NE
14	58/M	SAA	11	ATG + CsA	CR	3.76/1.77	14.4	208	59	0	NE
15	55/F	PNH	13	CsA	CR	3.54/2.29	14	111	79	39.16	0.001
		→NSAA

ANC, absolute neutrophil count; AS, anabolic steroids; ATG, antithymocyte globulin; CR, complete response; CsA, cyclosporine; F, female; GPI-AP⁻, glycosylphosphatidylinositol-anchored membrane proteins deficient; M, male; NE, not evaluated; NSAA, nonsevere aplastic anemia; PB, peripheral blood; PNH, paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; VSAA, very severe aplastic anemia.